<DOC>
	<DOC>NCT00944268</DOC>
	<brief_summary>To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open. Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.</brief_summary>
	<brief_title>Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Patients who achieve scores between 18 and 29 points in the Hamilton Scale for Anxiety; Individuals of any ethnic group male and female, aged above 18 years; Consent of the subject of research (a consent form signed). Patients with known hypersensitivity to any components of the formula; Pregnant women and nursing mothers; Patients with endogenous depression, schizophrenia, suicidal tendency; Patients with heart disease unabated, unabated kidney, liver and lung unabated unabated, at the discretion of the investigator; Addiction to drugs, including alcohol, at the discretion of the investigator; Patients who are using any medication that could interfere with the effect of the drug under study; Impossibility of compliance to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Passiflora, Crataegus and Salix</keyword>
	<keyword>Mild and Moderate anxiety</keyword>
	<keyword>Tablet</keyword>
	<keyword>To evaluate the efficacy and tolerability of the combination</keyword>
</DOC>